Ordinary login controls prove a user can access a system. Strong EPCS authentication also proves the prescriber is present and properly authorised at the moment an order is signed. That distinction matters because controlled substance prescribing needs end to end integrity, not just a successful session sign-in, especially when the workflow must protect against diversion and unauthorised orders.
Why strong EPCS authentication is more than a normal sign-in
Ordinary login controls answer a basic question: did the user successfully authenticate to the system? Strong EPCS authentication answers a stricter one: was the prescriber present, authenticated to a higher assurance level, and able to authorise this specific controlled-substance order at the point of signature? That difference is what turns login into a transaction control.
In practice, the control is tied to the prescribing act itself, not just to access to a portal. That is why strong EPCS authentication is designed to resist replay, shared account misuse, and post-login session abuse. A successful sign-in is necessary, but it is not sufficient on its own to protect order integrity.
For healthcare organisations, the distinction is especially important because prescribing workflows involve both clinical access and regulatory-grade accountability. A prescriber can be legitimately signed in and still fail the stronger requirement if the signing event does not provide the level of assurance needed for controlled substances. The Healthcare Identity Security Guide covers why this matters in clinical environments where access, shared workstations and EPCS intersect.
What ordinary login controls do not guarantee
Ordinary login controls usually prove that a user knows a password, possesses a second factor, or has an active session. They do not necessarily prove that the right person is present at the exact moment an order is authorised, and they do not always bind the assurance check to the high-risk action itself. That gap matters when the workflow has legal and safety implications.
Strong EPCS authentication is stricter because it is meant to reduce the chance that a compromised session, unattended workstation, reused credential, or delegated access path can be used to sign a controlled prescription. The control is therefore about both identity assurance and action integrity. The difference is not semantic, it is operational.
This is also why general authentication guidance, while useful, is not enough by itself. NIST’s SP 800-63 Digital Identity Guidelines helps frame assurance strength, and the MFA Guide explains how phishing-resistant factors and token theft risks change what “logged in” really means.
Why the distinction matters for controlled-substance integrity
Controlled-substance prescribing needs end-to-end integrity, not just authenticated access to a charting system. If an attacker, assistant, or compromised session can complete the order without the prescriber being properly present and authorised, the system has moved from access control failure to prescribing integrity failure. That is a much higher-impact problem.
Ordinary login controls are often sufficient for low-risk workflow entry, but they are not enough where the action itself creates regulated exposure. Strong EPCS authentication is intended to make the signing event materially harder to abuse than routine system access. The Passwordless and Passkeys Guide is useful context for phishing-resistant sign-in, but EPCS adds the extra requirement that the prescriber’s authority be validated at the transaction boundary.
That is why healthcare teams should think in terms of assurance at the point of prescribing, not just assurance at the point of entry. A control can be strong for general access and still be too weak for a controlled-substance signature workflow.
Risk and Threat Considerations
The main risk is false confidence: organisations may believe a successful login protects the prescription when the real exposure sits in the signing step. If the prescriber session is hijacked, the workstation is left unattended, or a lower-assurance login is reused for a higher-risk action, the control gap can enable diversion or unauthorised orders.
Failure mechanism: Attackers or insiders exploit the difference between “authenticated to the system” and “authorised to sign this order now.” Session theft, MFA fatigue, shared access, and unattended endpoints are common mechanisms that can break the intended assurance boundary.
Impact: The result can be fraudulent prescribing, controlled-substance diversion, audit findings, and patient-safety exposure. In the worst case, the organisation has a valid login trail but no reliable proof that the order was signed under the intended level of prescriber assurance.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-63, NIST SP 800-53 Rev 5 and CIS Controls v8 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-63 | Digital Identity Guidelines | EPCS assurance depends on strong authenticator and identity assurance levels. |
| Recommendation — Apply assurance levels and phishing-resistant authenticators at the prescribing step. | ||
| NIST SP 800-53 Rev 5 | IA-2 — Identification and Authentication (Organizational Users) | Prescribers are organizational users whose strong authentication must be verified. |
| IA-5 — Authenticator Management | EPCS depends on managing authenticators used for high-assurance signing. | |
| Recommendation — Require robust user authentication before permitting controlled-substance signing. Rotate and protect authenticators that support prescriber-signing workflows. | ||
| ISO/IEC 27001:2022 | A.5.15 — Access control | The distinction hinges on controlling access to a high-risk signing action. |
| A.8.5 — Secure authentication | Strong EPCS requires stronger authentication than ordinary login controls. | |
| Recommendation — Restrict prescription-signing access to authorised users and approved workflows. Use stronger authentication for EPCS signing than for routine system access. | ||
| CIS Controls v8 | CIS-5 — Account Management | Prescriber access, session handling and recovery paths are central to the control gap. |
| Recommendation — Tighten account lifecycle and recovery paths for prescriber accounts. | ||
Practitioner Guidance
What to verify: Confirm that the EPCS control is bound to the signing action, not just to portal access. If the policy only checks whether the user is “logged in,” treat that as a design gap rather than a control.
Decision rule: If a workflow can create or approve a controlled-substance order, require a higher-assurance step at signature time and re-check whether the session is still attributable to the prescriber before release.
What good looks like: The audit trail should show who signed, when they signed, how strong the prescriber authentication was, and whether the order was authorised under the required workflow conditions. If any of those elements are missing, the control is not yet strong enough.
Practitioner takeaway: Treat ordinary login as access to the system, but treat strong EPCS authentication as proof of authorised prescribing action. The control has to protect the order, not just the session.
Related resources from NHI Mgmt Group
- What is the difference between strong customer authentication and ordinary MFA?
- What is the difference between strong customer authentication and basic login in open banking?
- What is the difference between strong client authentication and least privilege?
- What is the difference between strong authentication and least privilege in cloud security?
